vs
Aurinia Pharmaceuticals Inc.（AUPH）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是Aurinia Pharmaceuticals Inc.的2.0倍（$151.1M vs $77.1M），Aurinia Pharmaceuticals Inc.同比增速更快（28.8% vs 3.6%），过去两年Aurinia Pharmaceuticals Inc.的营收复合增速更高（23.8% vs 5.1%）
Aurinia Pharmaceuticals是一家生物制药企业，专注于自身免疫疾病及肾脏疾病靶向疗法的研发与商业化，核心获批产品为用于治疗成人活动性狼疮性肾炎的Lupkynis，主要市场覆盖北美及欧洲地区。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
AUPH vs RGR — 直观对比
营收规模更大
RGR
是对方的2.0倍
$77.1M
营收增速更快
AUPH
高出25.2%
3.6%
两年增速更快
AUPH
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.1M | $151.1M |
| 净利润 | $210.8M | — |
| 毛利率 | 88.6% | 17.8% |
| 营业利润率 | 43.1% | 2.3% |
| 净利率 | 273.4% | — |
| 营收同比 | 28.8% | 3.6% |
| 净利润同比 | 14651.2% | — |
| 每股收益（稀释后） | $1.52 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AUPHRGR
| Q4 25 | $77.1M | $151.1M | ||
| Q3 25 | $73.5M | $126.8M | ||
| Q2 25 | $70.0M | $132.5M | ||
| Q1 25 | $62.5M | $135.7M | ||
| Q4 24 | $59.9M | $145.8M | ||
| Q3 24 | $67.8M | $122.3M | ||
| Q2 24 | $57.2M | $130.8M | ||
| Q1 24 | $50.3M | $136.8M |
净利润AUPHRGR
| Q4 25 | $210.8M | — | ||
| Q3 25 | $31.6M | $1.6M | ||
| Q2 25 | $21.5M | $-17.2M | ||
| Q1 25 | $23.3M | $7.8M | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $14.3M | $4.7M | ||
| Q2 24 | $722.0K | $8.3M | ||
| Q1 24 | $-10.7M | $7.1M |
毛利率AUPHRGR
| Q4 25 | 88.6% | 17.8% | ||
| Q3 25 | 88.9% | 15.1% | ||
| Q2 25 | 89.8% | 3.9% | ||
| Q1 25 | 86.3% | 22.0% | ||
| Q4 24 | 90.7% | 22.8% | ||
| Q3 24 | 91.1% | 18.5% | ||
| Q2 24 | 84.4% | 22.3% | ||
| Q1 24 | 84.6% | 21.5% |
营业利润率AUPHRGR
| Q4 25 | 43.1% | 2.3% | ||
| Q3 25 | 40.5% | -2.7% | ||
| Q2 25 | 28.7% | -15.6% | ||
| Q1 25 | 35.0% | 6.2% | ||
| Q4 24 | -2.8% | 7.8% | ||
| Q3 24 | 17.3% | 3.1% | ||
| Q2 24 | -2.6% | 6.9% | ||
| Q1 24 | -26.3% | 5.5% |
净利率AUPHRGR
| Q4 25 | 273.4% | — | ||
| Q3 25 | 42.9% | 1.2% | ||
| Q2 25 | 30.7% | -13.0% | ||
| Q1 25 | 37.4% | 5.7% | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 21.2% | 3.9% | ||
| Q2 24 | 1.3% | 6.3% | ||
| Q1 24 | -21.4% | 5.2% |
每股收益（稀释后）AUPHRGR
| Q4 25 | $1.52 | $0.22 | ||
| Q3 25 | $0.23 | $0.10 | ||
| Q2 25 | $0.16 | $-1.05 | ||
| Q1 25 | $0.16 | $0.46 | ||
| Q4 24 | $0.00 | $0.62 | ||
| Q3 24 | $0.10 | $0.28 | ||
| Q2 24 | $0.01 | $0.47 | ||
| Q1 24 | $-0.07 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.2M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $581.3M | $283.8M |
| 总资产 | $751.6M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AUPHRGR
| Q4 25 | $80.2M | $92.5M | ||
| Q3 25 | $72.9M | $80.8M | ||
| Q2 25 | $52.9M | $101.4M | ||
| Q1 25 | $66.1M | $108.3M | ||
| Q4 24 | $83.4M | $105.5M | ||
| Q3 24 | $36.6M | $96.0M | ||
| Q2 24 | $33.3M | $105.6M | ||
| Q1 24 | $63.9M | $115.3M |
股东权益AUPHRGR
| Q4 25 | $581.3M | $283.8M | ||
| Q3 25 | $365.8M | $279.6M | ||
| Q2 25 | $335.3M | $289.3M | ||
| Q1 25 | $350.2M | $321.5M | ||
| Q4 24 | $377.5M | $319.6M | ||
| Q3 24 | $388.0M | $314.9M | ||
| Q2 24 | $364.6M | $321.5M | ||
| Q1 24 | $359.5M | $332.0M |
总资产AUPHRGR
| Q4 25 | $751.6M | $342.0M | ||
| Q3 25 | $527.5M | $342.3M | ||
| Q2 25 | $502.6M | $349.5M | ||
| Q1 25 | $504.9M | $379.0M | ||
| Q4 24 | $550.6M | $384.0M | ||
| Q3 24 | $549.4M | $373.5M | ||
| Q2 24 | $523.5M | $376.7M | ||
| Q1 24 | $516.6M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.7M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | — | $12.3M |
| 自由现金流率自由现金流/营收 | — | 8.2% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | 0.22× | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势，按日历期对齐
经营现金流AUPHRGR
| Q4 25 | $45.7M | $15.5M | ||
| Q3 25 | $44.4M | $12.9M | ||
| Q2 25 | $44.2M | $14.7M | ||
| Q1 25 | $1.3M | $11.1M | ||
| Q4 24 | $30.1M | $20.0M | ||
| Q3 24 | $17.0M | $9.4M | ||
| Q2 24 | $15.8M | $18.7M | ||
| Q1 24 | $-18.6M | $7.3M |
自由现金流AUPHRGR
| Q4 25 | — | $12.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.6M |
自由现金流率AUPHRGR
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 4.1% |
资本支出强度AUPHRGR
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 1.3% |
现金转化率AUPHRGR
| Q4 25 | 0.22× | — | ||
| Q3 25 | 1.41× | 8.15× | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 0.06× | 1.43× | ||
| Q4 24 | 21.07× | — | ||
| Q3 24 | 1.19× | 1.98× | ||
| Q2 24 | 21.94× | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AUPH
| Products | $74.2M | 96% |
| License Collaboration And Royalty Revenue | $2.9M | 4% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
